Payment overview · 2025
General Payments
$253.46
12 reported records · 10 companies
Healthcare provider profile · identity verified
Muhammad Naeem, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CUMBERLAND, MD · NPI 1710186291
Verified facts
What the public records show
CMS Open Payments records show Muhammad Naeem, MD received $253.46 in general payments during 2025 across 12 reported records.
PFIZER INC. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Paxlovid.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.90 | 20.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.46 | 12.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.63 | 11.3% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $25.09 | 9.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.00 | 8.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.48 | 8.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.01 | 7.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.84 | 7.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.05 | 7.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.00 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $253.46 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.40 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.40 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.40 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.46 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.46 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $28.63 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 21 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
75 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
236 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 463 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 347 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 312 | 99 |
| Furosemide | Furosemide | 301 | 73 |
| Lisinopril | Lisinopril | 272 | 74 |
| Gabapentin | Gabapentin | 257 | 56 |
| Eliquis | Apixaban | 236 | 44 |
| Losartan Potassium | Losartan Potassium | 201 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 196 | 37 |
| Omeprazole | Omeprazole | 189 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 184 | 40 |
| Sertraline Hcl | Sertraline Hcl | 184 | 35 |
| Buspirone Hcl | Buspirone Hcl | 171 | 37 |
| Metformin Hcl | Metformin Hcl | 163 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 54 |
| Famotidine | Famotidine | 153 | 45 |
| Potassium Chloride | Potassium Chloride | 152 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 42 |
| Mirtazapine | Mirtazapine | 148 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 30 |
| Donepezil Hcl | Donepezil Hcl | 131 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 28 |
| Trazodone Hcl | Trazodone Hcl | 115 | 33 |
| Meloxicam | Meloxicam | 112 | 34 |
| Tramadol Hcl | Tramadol Hcl | 101 | 23 |
| Baclofen | Baclofen | 95 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 34 |
| Alprazolam | Alprazolam | 86 | 19 |
| Simvastatin | Simvastatin | 78 | 19 |
| Levetiracetam | Levetiracetam | 75 | 12 |
| Trulicity | Dulaglutide | 75 | 16 |
| Memantine Hcl | Memantine Hcl | 74 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 71 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 15 |
| Lorazepam | Lorazepam | 67 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 15 |
| Clonidine Hcl | Clonidine Hcl | 66 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 14 |
| Prednisone | Prednisone | 64 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 21 |
| Allopurinol | Allopurinol | 59 | 14 |
| Spironolactone | Spironolactone | 59 | 12 |
| Carvedilol | Carvedilol | 58 | 17 |
| Atenolol | Atenolol | 56 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 15 |
| Montelukast Sodium | Montelukast Sodium | 52 | 13 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Mupirocin | Mupirocin | 49 | 33 |
| Januvia | Sitagliptin Phosphate | 47 | 11 |
| Finasteride | Finasteride | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | suppressed |
| Enulose | Lactulose | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Valsartan | Valsartan | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 20 |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Labetalol Hcl | Labetalol Hcl | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 18 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Nystatin | Nystatin | 34 | 22 |
| Risperidone | Risperidone | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 30 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 18 |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 18 |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | 11 |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Levocarnitine | Levocarnitine (With Sugar) | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Lactated Ringers | Ringer's Solution,lactated | 19 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 14 |
| Fluconazole | Fluconazole | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Trimipramine Maleate | Trimipramine Maleate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $253.46 · 12 records | PFIZER INC. | ABRYSVO, AREXVY, ARISTADA, COMIRNATY, GEMTESA, LYBALVI, MOUNJARO, PAXLOVID, PREVNAR 20, SHINGRIX, The Cologuard Plus Collection Kit, VOQUEZNA, VYEPTI, Veozah, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error